Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2011 - 2022)

Cumberland Pharmaceuticals (CPIX) has 12 years of Accumulated Expenses data on file, last reported at $17.6 million in Q4 2022.

• For the quarter ending Q4 2022, Accumulated Expenses rose 102.9% year-over-year to $17.6 million; the trailing twelve-month figure through Dec 2022 stood at $17.6 million (up 102.9% YoY), and the FY2022 full-year result was $17.6 million, up 102.9% from the prior year.
• Accumulated Expenses advanced to $17.6 million in Q4 2022, from $8.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.6 million in Q4 2022 to a low of $8.7 million in Q4 2021.
• A 5-year average of $13.1 million and a median of $11.3 million in 2020 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 33.67% in 2019 and soared 102.9% in 2022, its largest moves.
• Tracing CPIX's Accumulated Expenses over 5 years: stood at $16.7 million in 2018, then sank by 33.67% to $11.1 million in 2019, then increased by 1.53% to $11.3 million in 2020, then fell by 22.98% to $8.7 million in 2021, then soared by 102.9% to $17.6 million in 2022.
• Business Quant data shows CPIX's Accumulated Expenses at $17.6 million in Q4 2022, $8.7 million in Q4 2021, and $11.3 million in Q4 2020.